18 and older, any sex, with Adenocarcinoma of the Pancreas. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression Free SurvivalPrimary· 1 year
Time from initiation of durvalumab to progression per RECIST 1.1 or death, whichever comes first. Per RECIST 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions compared to baseline sum of target lesions, or any new lesions. Confirmation of PD for participants who are deemed clinically stable by the Investigator should be acquired preferably at the next regularly scheduled imaging visit and no earlier than 4 weeks after the prior assessment of PD.
Group
Value
95% CI
Durvalumab Plus Radiation Therapy
53
51 – 53.5
Overall Response Rate (ORR)Secondary· 1 year
ORR is defined as the percentage of the patients who have a complete response (CR) or partial response (PR) as defined by RECIST 1.1. The patient's best overall response rate defined as the best response recorded from the start of the treatment until disease progression. Per RECIST 1.1, CR is defined as the disappearance of all target lesions; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR and PR requires a confirmatory scan preferably at the next regularly scheduled imaging visit and no earlier than 4
Group
Value
95% CI
Durvalumab Plus Radiation Therapy
0
Clinical Benefit Rate (CBR)Secondary· 1 year
The clinical benefit rate is the percentage of patients that have achieved a CR, PR, or stable disease (SD) as defined by RECIST 1.1. Per RECIST 1.1, CR is defined as the disappearance of all target lesions; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; PD is defined as at least a 20% increase in the sum of the diameters of target lesions compared to baseline sum of target lesions, or any new lesions; SD is defined as not meeting criteria for CR, PR, or SD. CR and PR requires a confirmatory scan preferabl
Group
Value
95% CI
Durvalumab Plus Radiation Therapy
1
Time to In-field ProgressionSecondary· 1 year
In-field progression is defined as PD according to RECIST 1.1 criteria (at least a 20% increase in the sum of the diameters of target lesions compared to baseline sum of target lesions, or any new lesions) within the original field or area where the participant had been treated with radiation therapy. Confirmation of PD for participants who are deemed clinically stable by the Investigator should be acquired preferably at the next regularly scheduled imaging visit and no earlier than 4 weeks after the prior assessment of PD.
The time to in-field progression is defined as the time from initiati
Group
Value
95% CI
Durvalumab Plus Radiation Therapy
53
51 – 53.5
Overall Survival (OS)Secondary· 1 year
OS is defined as the time from first treatment until death. Patients who are alive will be censored at the last date of patient contact.
Group
Value
95% CI
Durvalumab Plus Radiation Therapy
85
75 – 175
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 year, 3 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce
· Phase 2
· recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
· Phase 1
· not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
· Phase 2
· not yet recruiting
Other recruiting trials for Adenocarcinoma of the Pancreas
Currently open trials in the same condition.
NCT06582342 — Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?
· recruiting
NCT05116072 — Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
· Phase 1, PHASE2
· recruiting
Other Baptist Health South Florida trials
Trials by the same sponsor.
NCT07136350 — Nurse Caring Communication Engagement
· NA
· enrolling by invitation
NCT07222839 — Impact of Immersive Video Education on Cardiothoracic Surgery Anxiety and Outcomes
· NA
· enrolling by invitation
NCT07155876 — Exploring the Effect of Aromatherapy
· NA
· enrolling by invitation
NCT05553522 — Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
· Phase 1
· terminated
NCT04917224 — Study of LUNG Stereotactic Adaptive Ablative Radiotherapy
· NA
· withdrawn
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baptist Health South Florida
Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03490760.